The fundamental mission of the ETP at the MNI is to pursue and support bench-to-bedside-and-back translational studies in neurological and immune mediated diseases. The ETP has established itself as a major component of several such translational initiatives, including:
Over the last 4 years, the ETP has acted as the central platform for the first phase of the Canadian Pediatric Acquired Demyelinating Syndrome (ADS) Study. Application of serum and DNA samples collected from well-characterized children with CNS inflammatory attacks to the analytical resources present within the ETP and collaborating labs, have facilitated the study of early/initiating disease mechanisms and the pursuit of novel biomarkers of disease activity and prognosis.
The CIHR/EndMS New Emerging Team (NET) in Immune Regulation and Biomarker Development in Pediatric and Adult onset Autoimmune Disease is a highly integrated cross-disciplinary collaboration by a team that studies both pediatric- and adult-onset multiple sclerosis (MS), Type I Diabetes Mellitus (T1D) and inflammatory bowel disease (IBD). The ETP is assisting in the development of standardized and practical bioassays applied to high quality biological samples, with the aim to capture disease relevant biology in well-characterized cohorts of patients and healthy controls.
Neurobiology and neural immune interactions: ETP resources have helped to generate bioassays that investigate the differentiation and survival of oligodendrocytes, extension of neurites, and sublethal injury to neurons, astrocytes and oligodendrocytes. Validation of these assays, developed for industry sponsored studies, has generated proof-of-principle experiments that are now serving as the blueprint for broad-spectrum, higher throughput analyses of neurobiological readouts across healthy and treated patient populations.